Tricida, Inc.

Acrivon Therapeutics, Inc. brought its initial public offering to the US market a week later than originally planned and at different terms than it proposed a week earlier, but the cancer drug develo

Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been

Prime Medicine, Inc. ’s $175m initial public offering late on 19 October was only the second IPO in the US launched by a biopharmaceutical firm during the second half of 2022 that raised more than $10

Tricida, Inc. 's ambitions to bring the first drug to market to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis appear have been derailed by a failure in a large rena